<DOC>
	<DOCNO>NCT00922233</DOCNO>
	<brief_summary>A prospective , open-label , single arm , multicenter study evaluate efficacy , safety acceptability pericoital oral contraception levonorgestrel</brief_summary>
	<brief_title>Pericoital Oral Contraception With Levonorgestrel</brief_title>
	<detailed_description>This prospective , open-label , single arm , multicenter study evaluate efficacy , safety acceptability pericoital oral contraception levonorgestrel ( LNG ) . The objective study state study protocol follow : - To evaluate efficacy study regimen among woman sex 1-4 day month rely study regimen primary method contraception - To evaluate safety regimen , particular emphasis effect vaginal bleeding pattern anemia - To evaluate acceptability regimen The study enroll fertile woman reproductive age sex 6 day month , low risk sexually transmit infection ( STIs ) , contraindication progestin-only oral contraceptive , serious contraindication pregnancy , willing use investigational method contraception contraceptive method 6.5 month ( tablet contain 0.75 mg LNG use every sex act ) .</detailed_description>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Each woman enrol trial must meet follow inclusion criterion : Competent provide inform consent participate trial do . At least minimum age 18 45 year old . Had sex 1 4 day past month expect continue frequency next 6.5 month . At low risk sexually transmit infection ( STI ) , operationally mean neither partner knowledge follow : More one sexual partner currently expectation one sexual partner next 6.5 month Diagnosis human immunodeficiency virus ( HIV ) infection , hepatitis B hepatitis C Treatment STI within past 6 month , exclude recurrent genital herpes condyloma Sharing illicit injection drug equipment ever past . Willing use study regimen contraceptive method next 6.5 month ( except may also use condom need protection STIs ) . Wants avoid pregnancy least next 6.5 month . Willing accept uncertain risk pregnancy study . Gives correct answer informed consent quiz . Willing able follow study requirement . To eligible enrollment , woman must meet follow exclusion criterion : Pregnant verify pregnancy test enrollment . Has indication current subfecundity , specifically : Her last pregnancy end within last 8 week , few two menstrual period since resolution last pregnancy She normal monthly menses past 2 month She currently breastfeed She use hormonal contraceptive emergency contraceptive pill since onset last menstrual period Has receive injection long term injectable contraceptive last 9 month Currently intrauterine device Has sterilization procedure ectopic pregnancy Has diagnose clinician fertility problem Her partner sterilization procedure infertility diagnosis , knowledge . She currently know contraindication progestinonly pill , specifically include follow condition : Unexplained abnormal vaginal bleeding Deep venous thrombosis pulmonary embolus Active viral hepatitis Decompensated cirrhosis Liver tumor History breast cancer within past 5 year . Has breast mass examination . Has personal family history suggestive predisposition thrombosis . Has serious contraindication pregnancy ( medical condition use chronic medication isotretinoin thalidomide ) . Taking drug know interact progestin ( rifampicin anticonvulsant medication ) . Has previously participate study . Currently participate another medical research study . The site investigator designee perceive another reason exclude trial .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Contraception</keyword>
</DOC>